.
. Kyriazopoulou E, et al. Nat Med. 2021 Sep 3. doi: 10.1038/s41591-021-01499-z. Online ahead of print. Nat Med. 2021. PMID: 34480127
. Lehnertz B, et al. Blood. 2021 Sep 9:blood.2021010745. doi: 10.1182/blood.2021010745. Online ahead of print. Blood. 2021. PMID: 34499717
.
Signaling defects associated with insulin resistance in non-diabetic and diabetic individuals and modification by sex.
Haider N, Lebastchi J, Jayavelu AK, Batista TM, Pan H, Dreyfuss JM, Carcamo-Orive I, Knowles JW, Mann M, Kahn CR.
.
.
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
- Gluten intolerance a significant risk factor
- Infectious disease of the uterus
- Absence of an individual specific disease